RETINA-AI Health
Founded Year
2017Stage
Bridge | AliveTotal Raised
$13MLast Raised
$2.6M | 10 mos agoAbout RETINA-AI Health
RETINA-AI Health develops artificial intelligence software for diagnosing retinal and systemic diseases from images of the retina. The company's RETINA-AI Galaxy uses deep learning to automatically detect more than mild diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopathy (vtDR). The company was founded in 2017 and is based in Houston, Texas.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Expert Collections containing RETINA-AI Health
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
RETINA-AI Health is included in 2 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
10,944 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health
10,563 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
RETINA-AI Health Patents
RETINA-AI Health has filed 4 patents.
The 3 most popular patent topics include:
- Diseases of the eye and adnexa
- Dosage forms
- Drug delivery devices
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/12/2019 | 7/19/2022 | Machine learning, Artificial intelligence, Rare diseases, Classification algorithms, Diseases of the eye and adnexa | Grant |
Application Date | 8/12/2019 |
|---|---|
Grant Date | 7/19/2022 |
Title | |
Related Topics | Machine learning, Artificial intelligence, Rare diseases, Classification algorithms, Diseases of the eye and adnexa |
Status | Grant |
Latest RETINA-AI Health News
Dec 12, 2022
closes its bridge financing round during which it raised $2.6M, bringing the total raised so far by the company to $8.1M for the development of RETINA-AI Galaxy™ v2.0, a U.S. patent-protected multi-camera-compatible autonomous Artificial Intelligence (AI) diabetic retinopathy detection system. On Nov 3rd 2022, the company began enrollment in its Pivotal (Phase III) multi-center prospective clinical trial of the RETINA-AI Galaxy™ v2.0 (ClinicalTrials.gov ID: NCT05368623). Dr. Stephen G. Odaibo, Founder and CEO of RETINA-AI Health, Inc. 37 million Americans and 537 million people globally suffer from diabetes – each of whom needs at least one diabetic eye exam annually. Unfortunately, most do not receive the exam. AI can help, but thus far there are no AI systems approved for use with retinal cameras from more than one manufacturer – thereby constituting a bottleneck to access. That unmet need is what prompted the development of the RETINA-AI Galaxy™ v2.0. "This is all about increasing access to high quality specialized healthcare for all people," says Dr. Stephen G. Odaibo, CEO and Founder of RETINA-AI Health, Inc., who is a board-certified ophthalmologist, retina specialist, mathematician, software engineer, and an AI and Machine Learning expert. "We are keen that our technologies are developed to the highest scientific, regulatory, and ethical standards, and are accessible to people from all walks of life for which they are indicated – including people from a large diversity of racial and socioeconomic backgrounds. This is why we have invested so much of our time, expertise, and resources as a company to develop this multi-camera-compatible AI system. This motivation and focus is a key part of what sets us apart as a company," Dr. Odaibo says. The company projects that it will complete its ongoing Pivotal (Phase III) clinical trial of the RETINA-AI Galaxy™ v2.0 in the Spring of 2023, and will submit its U.S. FDA application shortly afterwards. ABOUT RETINA-AI Health, Inc. RETINA-AI Health, Inc. is a privately-held Delaware C-Corp founded in 2017 and headquartered in Houston Texas. The company is focused on building AI to transform healthcare and improve the outcomes of prevalent chronic diseases. It develops and deploys retina-based AI for detection of systemic chronic diseases at scale. RETINA-AI Health, Inc. has a strong unwavering commitment to adhere to the highest standards of quality and ethics, while continuously leading the world in healthcare AI innovation. Media Contact:
RETINA-AI Health Frequently Asked Questions (FAQ)
When was RETINA-AI Health founded?
RETINA-AI Health was founded in 2017.
Where is RETINA-AI Health's headquarters?
RETINA-AI Health's headquarters is located at 2925 Richmond Avenue, Houston.
What is RETINA-AI Health's latest funding round?
RETINA-AI Health's latest funding round is Bridge.
How much did RETINA-AI Health raise?
RETINA-AI Health raised a total of $13M.
Who are the investors of RETINA-AI Health?
Investors of RETINA-AI Health include Bill Smith and CrossCut Ventures.
Who are RETINA-AI Health's competitors?
Competitors of RETINA-AI Health include Aireen.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare RETINA-AI Health to Competitors
Eyenuk is focused on quickly and accurately identifying patients suffering from potentially blinding eye diseases and preserving their vision. Using computer vision and image analysis expertise, the company is developing a portfolio of products based on its proprietary retinal image analysis technology to identify and track the progression of eye diseases including diabetic retinopathy and age-related macular degeneration. The company was founded in 2010 and is based in Woodland Hills, California.
Thirona Retina specializes in the field of AI-assisted medical image analysis for eye disease screening, with RetCAD as its flagship product platform. It provides a software product using artificial intelligence that analyzes color fundus images for the presence of age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma. It was founded in 2014 and is based in Nijmegen, Netherlands.
Aireen is a non-invasive AI-based medical device company. It develops a medical technology designed to offer a non-invasive, painless screening of chronic diseases based on eye retina capture. Its technology uses artificial intelligence to detect diabetes from the image of an eye's retina, enabling patients to reduce the time and financial cost of a routine diagnosis by a doctor. The company was founded in 2018 and is based in Prague, Czech Republic.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
